• FirefoxInstall the new Firefox »
  •  Dow Down0.44% Nasdaq Down0.42%

    MannKind Corp. (MNKD)

    -NasdaqGM
    5.22 Up 0.02(0.38%) 4:00PM EDT
    |After Hours : 5.20 Down 0.02 (0.38%) 5:06PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    MannKind Corp.
    28903 North Avenue Paine
    Valencia, CA 91355
    United States - Map
    Phone: 661-775-5300
    Website: http://www.mannkindcorp.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:287

    Business Summary 

    MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MannKind Corp.

    Corporate Governance 
    MannKind Corp.’s ISS Governance QuickScore as of Mar 1, 2015 is 9. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 3; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Alfred E. Mann , 89
    Founder and Exec. Chairman
    1.32M0.00
    Mr. Hakan S. Edstrom B.Sc., M.B.A., 65
    Chief Exec. Officer, Pres and Director
    1.18M0.00
    Mr. Matthew J. Pfeffer CPA, 57
    Chief Financial Officer, Principal Accounting Officer and Corp. VP
    700.00K51.00K
    Dr. Juergen A. Martens Ph.D., 59
    Chief Operating Officer
    740.00K62.00K
    Dr. David B. Thomson Ph.D., J.D., 48
    Corp. VP, Gen. Counsel and Corp. Sec.
    615.00K496.00K
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders